Target
Muc16CD
1 product
6 abstracts
Abstract
A phase 1/2, first-in-human study of DS-3939a in patients with advanced solid tumors: A new DXd ADC targeting TA-MUC1.Org: Huntsman Cancer Institute at University of Utah Health, Legorreta Cancer Center at Brown University, Lifespan Cancer Institute,
Abstract
Antagonizing vasoactive intestinal peptide (VIP) receptors with Muc16CD-directed armored CAR T cells for pancreatic cancer.Org: Achieve Clinics,
Abstract
A phase 1/2 study of ubamatamab (REGN4018), a MUC16×CD3 bispecific antibody, administered alone or in combination with cemiplimab (anti–PD-1) in patients with recurrent ovarian cancer or MUC16+ endometrial cancer.Org: Lyon University Hospital, Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), EPSILYON, Université Claude Bernard Lyon 1, Gustave Roussy, Département de Médecine Oncologique, Peter MacCallum Cancer Centre, University of Melbourne, Prince of Wales Hospital and University of New South Wales,
Abstract
Deep learning-based approach to predict multiple genetic mutations in colorectal and lung cancer tissues using hematoxylin and eosin-stained whole-slide images.Org: Biomy Inc., Akita University Graduate School of Medicine, Keio University School of Medicine,
Product
TMZAbstract
Exploring expression levels of HER2, HER3, MET, Claudin18.2, and MUC16 across 16 cancer types using an artificial intelligence-powered immunohistochemistry analyzer.Org: Oncology Therapeutic Development, Lunit Inc., Samsung Medical Center, Sungkyunkwan University School of Medicine, Chonnam National University Medical School and Hwasun Hospital,
Abstract
Phase I clinical trial using a unique immunotherapeutic combination of MUC1-targeted CAR-T cells with PD-1-knockout in the treatment of patients with advanced esophageal cancer.Org: First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou JOYO Pharma, Guangdong Ruishun Biotech, China National Biotec Group,